Skip to main content

COVID-19 Resources

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.cdc.gov/coronavirus

Get the latest research information from NIH: https://www.covid19.nih.gov

Grant Details

Grant Number: 5R01CA240360-02 Interpret this number
Primary Investigator: Sussman, Elyse
Organization: Albert Einstein College Of Medicine
Project Title: Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia
Fiscal Year: 2021


Abstract

Project Summary Between 40-70% of children treated for acute lymphoblastic leukemia (ALL) on contemporary protocols exhibit measurable deficits in cognitive functioning, which negatively impacts school and occupational performance, and diminishes quality of life. However, the specific processing deficits contributing to poor cognitive functioning in survivors of childhood ALL and the implications for ongoing brain development are poorly understood. The goal of this project is to characterize treatment-related effects on brain functions (Aim 1), identify abnormal patterns of neural connectivity (Aim 2), and assess chronic effects of chemotherapy treatment on the development of cognitive skills (Aim 3) in childhood survivors. We achieve these aims by using a combination of behavioral, electrophysiological, and neuroimaging measures to demonstrate effects on neurocognitive function, brain activity and brain development following chemotherapy compared to healthy, matched controls. Our study is designed to identify the relative contributions of sensory processes, memory, and attentional mechanisms, and cortical-maturation delays to poor performance on standardized tests of cognition function. Our approach will lead to the development of a powerful set of tools for identifying children with persistent treatment-related changes in cognitive functioning due to exposure to toxic therapy. Results will differentiate the level at which processing deficits occur (Aims 1 and 2), and longitudinally assess cognitive development (Aim 3) and the associated development in brain function and pathways in survivors of childhood ALL. This contribution is significant because defining the loci of neurocognitive dysfunction caused by ALL treatment would guide the development of novel preventive, treatment, and intervention strategies.



Publications


None


Back to Top